16 / 31
Subgroup Analysis by PD-L1 Status
•
Important facts regarding PD-L1 status:
−
PD-L1 testing was not required
−
37% of patients with unknown PD-L1 status
−
PD-L1 status was obtained pre-CRT (getting a sample post-CRT medically not feasible)
−
PD-L1 expression-level cutoff of 1% was part of an
unplanned post-hoc analysis requested by a health authority
Overall Survival with Durvalumab versus Placebo after
Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC